Sofosbuvir/ledipasvir produces early cure for 100% of HIV/HCV coinfected patients

Treatment for 12 weeks with a coformulation of sofosbuvir and ledipasvir led to sustained response for all HIV/HCV coinfected patients with genotype 1 hepatitis C followed for 12 weeks post-treatment, according to interim findings from the ERADICATE study presented Thursday at the 49th EASL International Liver Congress in London.

http://ift.tt/1nb5eDn